论文部分内容阅读
目的:比较托特罗定联合萘哌地尔与单用托特罗定治疗女性膀胱过度活动症的疗效。方法:将35例女性膀胱过度活动症患者随机分为托特罗定联合萘哌地尔治疗组(18例)与单用托特罗定治疗组(17例),治疗时间为4周,以平均24 h排尿次数、平均24 h尿失禁次数、初始尿意容量(FDV)、最大膀胱压容量(MCBC)、最大尿流率(Qmax)为疗效指标,比较两组疗效。结果:2组间比较治疗前后24 h排尿次数、平均24 h尿失禁次数、初始尿意容量(FDV)、最大膀胱压容量(MCBC)、最大尿流率(Qmax),差异有显著性(P<0.05),联合用药组的上述指标的改善程度明显优于单独用药组。结论:托特罗定联合萘哌地尔治疗女性膀胱过度活动症的疗效优于单用托特罗定。
OBJECTIVE: To compare the efficacy of tolterodine in combination with naftopidil alone and tolterodine in treating female overactive bladder. Methods: A total of 35 female patients with overactive bladder were randomly divided into tolterodine combined with naftopidil group (n = 18) and tolterodine alone group (n = 17). The treatment time was 4 weeks. The average number of urination 24 h, the number of urinary incontinence 24 hours, initial urinary volume (FDV), maximum bladder pressure (MCBC) and maximum flow rate (Qmax) were used as efficacy indexes. Results: The urinary frequency, the number of urinary incontinence 24 hours, the initial urinary volume (FDV), the maximum bladder pressure (MCBC) and the maximum flow rate (Qmax) at 24 hours before and after treatment were significantly different between the two groups (P < 0.05). The improvement of the above indexes in the combination group was obviously better than that in the single drug group. Conclusions: The efficacy of tolterodine combined with naftopidil in the treatment of overactive bladder in women is superior to that of tolterodine alone.